Discovery Labs releases Phase IIa data

DSCO said its 8-patient Phase IIa trial of SuperVent aerosol solution of tyloxapol to treat cystic fibrosis showed a decrease in sputum interleukin-6 levels compared to placebo. DSCO announced in Marc...